• Who we are
    • About us
    • Our values
    • Environmental, social & governance
    • Therapeutic areas
  • What we do
    • Consulting (Acsel Health)
    • HEOR & market access
    • Scientific communications
    • Patient engagement
  • Insights
  • News & Events
  • Join us
    • Careers
    • Reasons to join
  • Contact us
  • Menu Menu

Publication Library / Publications

Long-Term Assessment of Healthcare Utilization Five Years After Respiratory Syncytial Virus Infection in US Infants

BACKGROUND

Respiratory syncytial virus (RSV) is the primary cause of respiratory tract infections in infants; however, current burden estimates report only the short-term effects of acute infection.

METHODS

Infants with RSV and ≥24 months continuous enrollment were retrospectively identified from the Truven MarketScan® database (01JAN2004-30SEP2015). Exposed infants (n=38,473) were propensity-score matched to non-exposed controls (n=76,825) by baseline characteristics and gestational age. 5-year cumulative all-cause, asthma/wheezing, and respiratory-related hospitalization, and physician and emergency room healthcare-resource utilization rates were assessed.

RESULTS

During follow-up, RSV cohorts had higher average all-cause cumulative hospitalization rates/100 patient years compared with controls; early premature, 79.9 (95% CI: 41.7, 118.2; P<.001; n=213), premature 18.2 (95% CI: 0.8, 35.7; P=.04; n=397), late premature 34.2 (95% CI: 29.1, 39.2; P<.001; n=4446), full-term 16.1 (95% CI, 14.9, 17.4; P<.001; n=33,417). Cumulative physician and emergency room visit rates were also higher for RSV infants. Asthma/wheezing accounted for 10-18% of total 5-year healthcare-resource utilization.

CONCLUSIONS

Infant RSV infection has a significant long-term healthcare-resource utilization impact for at least the following 5 years across gestational ages, mostly in the first 2 years following infection. Systematically collecting healthcare-resource utilization data will be important for cost-effectiveness evaluations of RSV interventions in planned or ongoing trials.

Authors VV Chirikov, EAF Simões EAF, M Botteman, A Kuznik, Y Kwon,
Journal The Journal of Infectious Diseases
Therapeutic Area Infectious diseases and vaccines
Center of Excellence Health Economic Modeling & Meta-analysis
Year 2019
Read full article

Services

  • Consulting
  • HEOR & market access
  • Scientific communications
  • Creative communications
  • Patient engagement

Company

  • About Us
  • Our values
  • Environmental, social & governance
  • Our commitment to rare disease
  • Careers
  • Reasons to join
  • News & insights
  • Events
  • Locations & contact

Legal and Governance

  • Terms of use
  • Privacy notice
  • Cookie policy
  • IT security measures
  • Modern slavery statement
  • Disclosure UK – ABPI
  • Looking for OpenHealth Company?
  • Legal statements & documents
  • Global ethical business conduct code
  • Suppliers
footer-logo-mark
  • Twitter
  • Linkedin
  • Instagram
  • Facebook

© Copyright OPEN Health 2025. All rights reserved. OPEN Health is a registered trademark.

backtotop-arrow
Scroll to top